Evaxion's Cancer Immunotherapy Shows Antitumor Effect In Early-Stage Melanoma Study

Loading...
Loading...
  • Evaxion Biotech A/S EVAX has announced results from its Phase 1/2a trial of EVX-01 in metastatic melanoma.
  • Data from the trial showed that EVX-01 in combination with a PD-1 checkpoint inhibitor was safe, with only mild and moderate adverse events observed.
  • Combined therapy with EVX-01 demonstrated an objective response rate of 67% across all nine patients, including 22% Complete Response (CR) and 44% Partial Response (PR). 
  • Among the four patients on the highest two doses, there was an objective response rate of 75%. 
  • Three patients with Stable Disease (SD) for 10, 8, and 9 months on anti-PD1 treatment alone achieved CR, CR, and PR, respectively, following EVX-01 administration.
  • The company expects to start a Phase 2b trial with EVX-01 in December 2021.
  • Evaxion also unveiled interim data from the Phase 1/2a trial of EVX-02 in adjuvant melanoma.
  • Data from the first patients in the trial showed T-cell activation, even in assays that had not been prestimulated.
  • The company aims to initiate a Phase 2 trial with EVX-02 in an adjuvant setting in Q2 of 2022.
  • Evaxion will host a webcast and conference call today at 8:00 a.m. EDT.
  • Price Action: EVAX shares are up 1.32% at $6.80 on the last check Thursday.
Posted In: BiotechNewsHealth CareGeneralBriefscancerPhase 1 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...